Resources Repository
-
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Priority Setting/Ethics | Preferences/Values | Health Outcomes | Economics/Finance | Chronic Disease/Risk | Costing Methods | Value of Information | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Operations Research | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Health Systems | Policy/Regulation | Business/Industry | Health/Medicine | Science/Technology | Global -
ReportPublication 2017Economic Value of Informal Mental Health Caring
Caregivers, family and friends play a significant role in supporting people with mental illness, and …
Caregivers, family and friends play a significant role in supporting people with mental illness, and it has long been recognized that informal carers constitute a significant ‘hidden’ workforce in Australia. Faced as Australia is with an ageing population and burgeoning chronic disease, data on the contribution that carers make and the consequent savings to governments and other ‘payers’ need to be articulated. This report attempts to put a ‘value’ on informal caring for those with mental illness.…
Preferences/Values | Health Outcomes | Economics/Finance | Chronic Disease/Risk | Costing Methods | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Mental Health | Health Systems | Health/Medicine | Oceania -
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Priority Setting/Ethics | Preferences/Values | Economics/Finance | Chronic Disease/Risk | Evidence Synthesis | Value of Information | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Mental Health | Health Systems | Business/Industry | Government/Law | Health/Medicine | Science/Technology | North America | Europe -
ArticlePublication 2016Measuring Benefits of Opioid Misuse Treatment: HRQOL of Opioid-Dependent Individuals and Spouses
This study sought to understand how the general public views the quality of life effects …
This study sought to understand how the general public views the quality of life effects of opioid misuse and opioid use disorder on an individual and his/her spouse, measured in terms used in economic evaluations. The study design was a cross-sectional internet survey of a US population-representative respondent panel conducted December 2013-January 2014, with a total of 2054 randomly selected adults, of whom 51.1% were male. The mean individual utility ranged from 0.574 for active injection…
Preferences/Values | Health Outcomes | Economics/Finance | Chronic Disease/Risk | Mental Health | Health/Medicine | North America -
ArticlePublication 2022Health and Financial Risk Protection Outcomes in Economic Evaluations
Extended cost-effectiveness analysis was developed to evaluate health interventions in terms of level and distribution …
Extended cost-effectiveness analysis was developed to evaluate health interventions in terms of level and distribution of health gains and financial risk protection. This information is typically presented in a joint display format. This article develops and applies an algebraic money-metric formulation that incorporates all disaggregated outcomes and finds that ranking of health interventions is sensitive to the decision maker’s aversion to inequality across income groups and that financial risk protection gains are most important to…
Priority Setting/Ethics | Economics/Finance | Chronic Disease/Risk | Cost-Effectiveness Analysis | Social Determinants | Health/Medicine | Global -
ArticlePublication 2022Equity Impact of Minimum Unit Pricing of Alcohol
South Africa experiences significant levels of alcohol-related harm. Recent research suggests minimum unit pricing (MUP) …
South Africa experiences significant levels of alcohol-related harm. Recent research suggests minimum unit pricing (MUP) for alcohol would be an effective policy, but high levels of income inequality raise concerns about equity impacts. This paper quantifies the equity impact of MUP on household health and finances in rich and poor drinkers in South Africa. Authors estimate MUP would reduce consumption more among the poorest than the richest drinkers. A MUP policy in South Africa has…
Priority Setting/Ethics | Economics/Finance | Chronic Disease/Risk | Social Determinants | Policy/Regulation | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2016Health and Economic Benefits of Public Financing of Epilepsy Treatment in India
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of …
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of publicly financed national epilepsy programs in India that provide (1) first line antiepilepsy drugs (AEDs), (2) first- and second-line AEDs, and (3) first- and second-line AEDs and surgery. Outcome measures include disability-adjusted life years (DALYs) averted, and cost per DALY averted. Economic benefit measures estimated include out-of-pocket (OOP) expenditure averted and money-metric value of insurance. All three scenarios represent a…
Priority Setting/Ethics | Economics/Finance | Chronic Disease/Risk | Microsimulation | Cost-Effectiveness Analysis | Health/Medicine | Asia & Pacific -
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Health Outcomes | Economics/Finance | Chronic Disease/Risk | Costing Methods | Evidence Synthesis | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Global Governance | Government/Law | Health/Medicine | Science/Technology | Global -
ReportPublication 2015DCP3: Cancer
This report from the World Bank is the third volume of the Disease Control Priorities, …
This report from the World Bank is the third volume of the Disease Control Priorities, Third Edition (DCP3) series. It presents data on the complex patterns of cancer incidence and deaths globally, and offers evidence on effective measures to control cancers. This report identifies settings in which cancer treatment may be ineffective or wasteful, and offers alternative cancer care packages that are cost-effective and better suited to low-resource environments. The Disease Control Priorities Network (DCP)…
Health Outcomes | Economics/Finance | Chronic Disease/Risk | Costing Methods | Evidence Synthesis | Cost-Effectiveness Analysis | Health Systems | Global Governance | Health/Medicine | Global